Analysts think PDSB stock price could increase by 280%
Dec 05, 2024, 12:25 PM
-24.19%
What does PDSB do
PDS Biotechnology, based in Princeton, New Jersey, develops clinical-stage immunotherapies for various cancers, including its lead product PDS0101, which targets HPV16. The company went public on October 1, 2015, and has 25 employees.
7 analysts think PDSB stock price will increase by 279.53%. The current median analyst target is $8.16 compared to a current stock price of $2.15. The lowest analysts target is $4.54 and the highest analyst target is $22.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
